Therapy option for genetic diseases

17.05.2019

The University of Vienna reports a paper which is firstauthored by MolTag student Xingyu Chen (Weinzinger Group): "Computational identification of novel Kir6 channel inhibitors".

The developed strategy is not only cost-effective, it can be used for many more protein defects and provides valuable insights into the side effects of already approved drugs.

 

Researchers are looking for new applications for already approved drugs

Breathe, think or hear - almost all the vital functions of our body depend on ion channels functioning properly. Defects in these proteins, caused by point mutations, can trigger many hereditary diseases. Researchers from the Faculty of Life Sciences at the University of Vienna and the Medical Center of the University of Utrecht are developing computer-aided methods to analyze the efficacy of already approved drugs for new applications in the area of rare genetic disorders. The results were recently published in the renowned journal "Frontiers in Pharmacology".

A rosiglitazone molecule bound to an ion channel. Anna Weinzinger and her team used this drug to find new therapeutic options for rare ion channel diseases (© Anna Weinzinger).

More News

03.12.2024
 

Nathalie Agudelo Dueñas successfully defended her PhD Thesis at ISTA - Congratulations!

19.08.2024
 

We congratulate Aljoša Smajić and Theres Friesacher on their successfull PhD Thesis defense!

15.04.2024
 

Congratulations to Nadja Singer, TheoChem Group, UniVie!